Development and evaluation of Desvenlafaxine loaded PLGA-chitosan nanoparticles for brain delivery
Depression is a debilitating psychiatric condition that remains the second most common cause of disability worldwide. Currently, depression affects more than 4 per cent of the world’s population. Most of the drugs intended for clinical management of depression augment the availability of neurotransm...
Main Authors: | Gui-Feng Tong, Nan Qin, Li-Wei Sun |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-09-01
|
Series: | Saudi Pharmaceutical Journal |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1319016416301372 |
Similar Items
-
Drug–drug interactions involving antidepressants: focus on desvenlafaxine
by: Low Y, et al.
Published: (2018-02-01) -
Comparative efficacy and safety of escitalopram, desvenlafaxine, and vortioxetine in the acute treatment of anxious depression: A randomized rater-blinded, 6-week clinical trial
by: K.-S. Oh, et al.
Published: (2022-06-01) -
Multidisciplinar treatment in postpartum depression. Coordinated attention of psychiatrist and midwife: use of desvenlafaxine while breastfeeding
by: S.S. Sánchez Rus, et al.
Published: (2022-06-01) -
Anticonvulsant effects of desvenlafaxine on modulating brain monoamine and oxidative stress in mice
by: Khalid Saad Alharbi
Published: (2021-08-01) -
Comparative efficacy and safety of escitalopram versus desvenlafaxine in postmenopausal women with depression and anxiety: A randomized, open-label, comparative trial
by: Sonia Shinde Mahajan, et al.
Published: (2019-01-01)